Exposure to particulate matter and ozone has severe repercussions on public health in the United States and globally. Fine particulate matter (or PM~2.5~, particulate matter with aerodynamic diameter of 2.5 μm or less) has been associated with exacerbations of asthma and chronic obstructive pulmonary disease, cardiovascular disease mortality, and lung cancer ([@bib1]--[@bib4]). Ozone exposure has been linked to increased risks for asthma exacerbations and other respiratory illnesses, as well as to cardiovascular disease mortality ([@bib5], [@bib6]). Fossil fuel combustion--related emissions of particulate matter and precursors of ozone have been estimated to cause approximately 210,000 premature deaths annually in the United States ([@bib7]). Further, combustion-related emissions that affect air quality also are the major drivers of climate change. There is new evidence that the effect of climate change on wildfires could double the numbers of premature deaths resulting from fine particulate matter exposure by 2100 ([@bib8]).

The National Ambient Air Quality Standards (NAAQS), established by the U.S. Environmental Protection Agency (EPA) under the Clean Air Act, are the federal standards for air quality levels that are designed to protect the health of even the most vulnerable populations with a margin of safety. As part of the process for establishing the NAAQS, the U.S. EPA reviews and evaluates the "most policy-relevant science, including key science judgments that are important to inform the development of the risk and exposure assessments," in a process called an Integrated Science Assessment ([@bib9]).

U.S. EPA review of the science has relied on investigations such as the Six Cities Study, which initially found that exposure to fine particulate matter was associated with premature mortality and later found that reductions in fine particulate matter concentrations with EPA enforcement were associated with a decrease in mortality ([@bib10]). The U.S. EPA estimated in 2011 that control of particulate matter will result in 230,000 adult lives saved by 2020 ([@bib11]).

Multicity studies have provided evidence for the associations of fine particulate matter and ozone exposures with cardiopulmonary mortality, but not for morbidity. National data on hospitalizations are only available from Medicare, the U.S. system that provides health insurance for adults 65 years and older, and therefore may not be representative of other populations. As noted in this issue of the *Journal* by Strosnider and colleagues (pp. [882--890](10.1164/rccm.201806-1147OC)), evidence for morbidity effects of these pollutants on populations not covered by Medicare has only been found in single-city studies ([@bib12]). Reliance on these single-city studies for this purpose has been problematic, however, as the characteristics of air pollution and population characteristics vary by city, along with each study's methodology, which makes it difficult to pool these studies to form an evidence base that can be generalized to reflect the U.S. population, let alone populations in other countries.

Strosnider and colleagues have accessed a unique database, maintained by the National Environmental Public Health Tracking Network ([@bib13]), which contains emergency room visit data for conditions related to environmental exposures, such as respiratory illness. Using daily data at the county level from 17 states, representing 45% of the U.S. population, they were able to analyze associations among ozone, fine particulate matter, and respiratory emergency room visits for all ages in this sample. Ambient air pollution levels were modeled and downscaled to census tract centroids and population-weighted to the county level. Using a two-stage process, the authors fit time-series models and then distributed lag models to account for air pollution effects up to 1 week after exposure, adjusting for pollutants, temperature, dew point, and other variables.

In general, the results of Strosnider and colleagues support the U.S. EPA's determination of a likely causal link between exposures to either fine particulate matter or ozone and respiratory illness ([@bib12]). However, for the first time, they found that fine particulate matter exposure was more strongly associated with respiratory emergency department visits among children, rather than adults. In contrast, effects were stronger among adults than children for ozone exposure--respiratory emergency department visit relationships. Other pollutant/illness associations they examined also yielded differences by age group. These findings provide evidence that reliance on Medicare data for estimating effects of ozone and fine particulate matter may not accurately estimate effects on populations younger than 65 years. As noted by the authors, age differences in the pollution effects of respiratory illness are supported by varying rates of emergency department visits for respiratory outcomes by age, disease pathology, age-specific patterns of exposure, and even pollutant characteristics.

There are limitations in any study. Although the authors used a robust approach in their analyses, model misspecification, that is, that their statistical model inadvertently missed important variables or proposed a wrong statistical functional form, could always be a possibility. However, the authors conducted sensitivity analyses that indicated that this is unlikely. Misclassification of the respiratory outcomes, if present, also does not appear to be a likely candidate to bias the study results in a particular direction. Exposure error in the pollution model (but likely random with respect to the outcome) and the national representativeness of the final sample are also concerns that may limit the usefulness of the study. However, the estimates provided here are the best evidence to date of age differences in the effects of ozone and fine particulate matter on respiratory illness, which will be very valuable in assessing whether the NAAQS need to be reevaluated.

Ideally, the results of this study would be used in U.S. EPA rulemaking, but it is important to note that these data are based on confidential emergency room visit records, which are maintained by state agencies and were aggregated to protect patient privacy. The currently proposed transparency (so-called "Secret Science") rule by the U.S. EPA would prohibit regulators from considering studies for review in rulemaking that do not provide the underlying data ([@bib14]). If this rule is approved, then it is possible that these study findings might not be taken into consideration for any changes in the NAAQS on fine particulate matter or ozone, as they are based on personal patient data. In fact, the seminal Six Cities Study results on fine particulate matter and mortality would probably also not be able to be used under the proposed rule. This would be unfortunate, as the best available science would not be included in U.S. EPA's rulemaking, and thus would not provide the best NAAQS to protect the nation's public health. Other recent actions by the U.S. EPA, including disbanding expert science panels that made recommendations on new standards for ozone and particulate matter, as well as moves to eliminate consideration of health cobenefits in calculating costs of pollution rule-making, also bring into question the agency's commitment to defend the public from exposure to harmful levels of these contaminants.
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